INTRODUCTION
With the discovery of tumor antigens [1] [2] [3] [4] , cancer immunology entered a new era where efforts to control cancer could be focused on the mechanistic principles of improving tumor-specific T-cell responses. The concepts of T-cell help [5] and natural tolerance induced by regulatory T-cells (Tregs) [6] were both established after the discovery of tumor antigens, and provided additional knowledge of mechanisms that promote or hinder cancer immune surveillance. Interleukin-10 (IL-10) was first recognized as a T-helper-2 (TH2) cytokine that modulates the growth and/or differentiation of innate immune cells, keratinocytes, and endothelial cells and suppresses the activation and effector functions of T-cells [7] . Simplistically, protective cytotoxic responses require CD4 þ T-cell help [8] [9] [10] [11] and are driven by the TH1 cytokines interferon (IFN)-g and IL-12. By contrast, inflammatory responses produced by the TH2 committed CD4 þ T-cells are a diversion if not an obstacle to effective transplant and tumor rejection by cytotoxic T-cells [12] [13] [14] . IL-10 and transforming growth factor (TGF)b that are produced by Tregs are expected to be major obstacles to CD8 þ T-cell-mediated tumor lysis [15] and cancer immune therapy [16] . Defying this expectation, protective roles for IL-10 in cancer are emerging that stimulate a fresh look at the functions of this cytokine and of its cellular sources [17] . IL-10 is now recognized not only as the most potent anti-inflammatory cytokine but also for enabling cancer immune surveillance and tumor rejection. This review addresses the controversial functions of IL-10 in cancer and their potential value for cancer immune therapy.
INTERLEUKIN-10 AND SUPPRESSION OF IMMUNE RESPONSE
IL-10 was initially heralded as a major immune suppressive factor that was critical for induction of tolerance through inhibition of the TH1 immune response and T-cell cytotoxic activity [49] [50] [51] [52] . IL-10 was shown to impair the proliferation, cytokine production, and migratory capacities of effector T-cells [50] . Elevated levels of IL-10 obstructed cytolytic activity in grafted tumors [53] [54] [55] [56] , and conversely the blockade of IL-10 in animal models facilitated rejection of transplanted tumors [57] [58] [59] [60] . The suppressive activity of IL-10 was reported to be direct, based primarily on in-vitro experiments [49, [61] [62] [63] [64] [65] [66] . However, there is evidence suggesting that much of the suppression attributed to IL-10 is indirect and cell-mediated [67] .
Professional antigen-presenting cells, also known as dendritic cells, are important targets of action of IL-10. In earlier studies, IL-10 downregulated expression of major histocompatibility complex (MHC) class II and costimulatory molecules CD80/B7-1 and CD86/B7.2, and TH1 cytokines including IL-12 by dendritic cells [50, 68, 69] (reviewed in [70] ). T-cells that were activated in the presence of IL-10 or dendritic cells previously treated with IL-10 failed to respond to restimulation, and were described as anergic [64, 71] . Tolerogenic dendritic cells produced IL-10 [21, 72, 73] , and autocrine activation of the IL-10 receptor (IL-10R) signaling helped to maintain dendritic cells in an immature tolerogenic state [50, 74] . IL-10 expressing dendritic cells were shown to generate Tregs and Tr1 cells, which were also IL-10-producing cells [75] [76] [77] [78] . Furthermore, IL-10 contributed to sustained expression of Foxp3 [46, 79] , TGFb-receptor-2 [80] , and TGFb [81, 82] by recently activated Tregs, thus stabilizing Treg phenotype and functions [67, 81] . IL-2 enhanced the expression of IL-10 by Tregs in a signal transduction and activation of transcription (STAT) 5-dependent manner [83] . Tregs in turn catalyzed the generation of Tr1 cells through secretion of IL-27 [84] . IL-27, a member of the IL-12 cytokine family, induced both TH1 development and production of IL-10 by CD4 þ T-cells [84] [85] [86] . Tr1 cells were also generated through the direct actions of IL-10 and IFN-a [87, 88] or through antigen presentation by tolerogenic IL-10-producing dendritic cells [72, 73, 89] . These observations showed that much of the immune suppression that is attributed to IL-10 in vivo can be accounted for by the generation and the complex immune modulatory mechanisms of action of Tregs and Tr1 cells.
The impact of IL-10 on immune homeostasis is spatially and temporally controlled. Naive CD4 þ T-cells were shown to be more sensitive than memory T-cells to IL-10, explained by down-regulation of IL-10R upon T-cell activation [50, 69, 90] . For example, Leishmania major vaccination produced more robust TH1 responses when IL-10 was limiting at the time of antigen priming [91] . Also, neutralization of endogenous IL-10 with anti-IL-10 mAb inhibited the development of insulin-dependent diabetes mellitus when performed early in mice life (priming phase) [92] , whereas the same treatment
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had no influence on the disease when given to older animals (memory phase) [93] . IL-10 could also compromise immune surveillance by changing immunogenicity of the antigen-presenting cell through down-regulation of transporter associated with antigen processing, and therefore antigen presentation by MHC-I and human leukocyte antigen-I [94, 95] . In fact, both TH17 and TH2 cells express IL-10, and there is good reason to expect IL-10 to work in a negative feedback loop to control activation of Thelper cells [96] .
Mechanistically, ligation of IL-10R on dendritic cells triggers phosphorylation of janus kinases that in turn activate STAT3 [97] [98] [99] . STAT3 is critical for the expression of IL-10 but is also known to activate the expression of proinflammatory cytokines including IL-6. Interestingly, the IL-10-mediated activation of STAT3 is anti-inflammatory. This is achieved through IL-10R signaling through lymphocytic activation molecule (SLAM), Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), and suppressor of cytokine signaling 3 (SOCS3) [100] . SLAM activates SHP-1 that dephosphorylates and inactivates the costimulatory receptors CD28, inducible T-cell costimulator (ICOS), and CD2 [101, 102] . Dephosphorylation inhibits the recruitment of phosphatidylinositol-3-kinase and blocks costimulatory signaling [90, [103] [104] [105] [106] [107] (for reviews see: [17, 80] ). Simultaneously, SOCS3 suppresses STAT-dependent signaling of inflammatory cytokines IL-6 [108] , tumor necrosis factor a (TNF-a), and IL-1b [109] . SOCS3 also suppresses signaling through the IL-23R and the expression of IL-17 in inflammatory TH17 T-cells [110] . Inhibition of proinflammatory cytokines is critical for generating functional extrathymic Tregs, as exposure of Tregs to IL-6 alone can compromise their lineage commitment and ability to suppress inflammation functions [111] [112] [113] . Thus, IL-10R signaling utilizes STAT3 but avoids the inflammatory consequences of action of STAT3.
INTERLEUKIN-10 AND IMMUNE STIMULATION
The immune suppressive action of IL-10 was so attractive that it overshadowed the almost concomitant discovery of its stimulatory effects on thymocytes, B cells, and mast cells [24, 114, 115] , and the interesting fact that the human IL-10 gene was first cloned from a T-cell line that also secreted IFN-g [116] . A growing literature is revealing pleiotropic functions of IL-10 that include T-cell activation and tumor rejection. It has been even argued that many of the attributes of IL-10 that were associated with immune suppression are equally likely to enhance immune activation [67] .
Stimulatory effects of IL-10 on T-cells and natural killer (NK) cells are known. IL-10 in combination with IL-2 substantially increased the frequency of CD8 þ T-cells and augmented their cytolytic activity [117] . In the OVA-specific OT1 model, exposure of CD8 T-cells to IL-10 during priming increased T-cell survival and numbers but not proliferation [118] . IL-10 in combination with IL-18 increased the frequency and cytolytic activity of NK cells [119] . These immune stimulatory functions of IL-10 had biologically meaningful consequences. Expression of IL-10 by tumor cells or antigen-presenting cells was protective in tumor transplant models [120, 121] . Ectopic expression of IL-10 in mouse B16 melanoma cells induced NK cell-mediated shrinkage of the transplanted tumors [122] . Similarly, expression of IL-10 reduced growth of the mouse TSA mammary adenocarcinoma cells upon transplantation [123] . Polyposis prone APC D468 mice that were rendered IL-10 deficient had a significant delay in the onset of small intestine polyposis that coincided with increased intrapolyp cytotoxic activity at the onset of polyposis, suggesting improved priming of polyp-specific Tcells (Dennis et al. 2013, article submitted). There are also reports of protective benefits of systemic delivery of IL-10 [124, 125] . A comprehensive study of the antitumor properties of IL-10 used multiple mouse tumor models including both chemically induced tumors and transplanted tumor cells [126 && ]. In this study, IL-10 induced several essential mechanisms of antitumor immune surveillance: infiltration and activation of intratumoral tumor-specific cytotoxic CD8 þ T-cells, expression of IFN and granzymes by CD8 þ T-cells, and enhancement of intratumoral antigen presentation. Consequently, IL-10 deficiency weakened tumor immune surveillance, whereas transgenic overexpression of IL-10 or treatment with pegylated IL-10 protected mice from carcinogenesis. Thus, IL-10 stimulated immune responses by modulating the quality of antigen presentation and influencing lymphocyte differentiation and lineage commitment. The need for IL-10 in TH1 lineage commitment suggests that it may have a role in establishing CD8 T-cell memory. Our observations in a mouse model of hereditary polyposis support these findings. In contrast to IL-10 competent mice that have prolonged intrapolyp cytotoxicity and never developed invasive lesions, IL-10 deficient mice rapidly lost their intrapolyp cytotoxicity, and their lesions progressed into large invasive cancers, suggesting an abortive immune response that did not lead to establishment of T-cell memory (Dennis et al.
2013, article submitted).
The immune stimulatory functions of IL-10 were corroborated by the studies of human T-cells, in which IL-10 enhanced IL-2-stimulated proliferation of both human CD4 þ and CD8 þ T-cells by increasing cell division after activation, and augmented IL-2 but not IL-15-induced cytotoxicity of intestinal lymphocytes against colon cancer [127] . IL-10 in combination with IL-2 consistently increased the cytotoxic activity of human papillomavirus E7-specific CD8 þ cytolytic T-cells, whereas combinations of IL-2 and IFNg or IL-12 or TGF-b failed to do the same [128] . In addition, although IL-10 inhibited the ability of dendritic cells to generate allospecific cytotoxic activity, IL-10 in combination with IL-2 and anti-CD3 activated and promoted growth of human CD8 þ T-cells [129] . Finally, IL-10 effector CD4 þ T-cells with no immune regulatory functions have been described that are generated by the treatment of naive CD4 þ T-cells with TGF-b and IL-4 [130] .
Altogether, these observations support the provocative view that IL-10 is essential for TH1 and CD8 cytotoxic T-cell responses. These also raise questions as to the mechanisms by which IL-10 stimulates immunity, how these differ from the mechanisms by which IL-10 suppresses immunity, which of these mechanisms of action is direct and which indirect result of IL-10R signaling in effector T-cells, and to what extent the tissue environment determines the immunologic outcome of the action of IL-10.
INTERLEUKIN-10 AND SUPPRESSION OF INFLAMMATION AT ENVIRONMENTAL INTERFACES
Focal inflammation can improve antigen uptake and presentation leading to better specific CD8 þ T-cell responses and effective antitumor immune surveillance [131] [132] [133] [134] [135] [136] . However, among the T-cells that infiltrate the intestines, the cytolytic status of CD8 T-cells is unknown, whereas there is evidence suggesting that the intestine infiltrating CD4 þ cells can be cytolytic [137 && ]. The majority of CD8 þ Tcells that infiltrate the intestines are either anergic or immune suppressive [138] . The intestines are also the major extrathymic sites of generation of antiinflammatory Tregs [139] as well as proinflammatory TH17 cells [140] . Here, a fine balance between anti-inflammatory and proinflammatory T-cells critically maintains microbes at bay while providing growth and repair functions [141] . Deregulation of inflammation in the colon predisposes to inflammatory bowel diseases [142] [143] [144] [145] . Inflammation is an inherent component of sporadic colon cancer progression [146, 147] . TH17 cells and cytokines are elevated in human colon cancer tumors [148 && ] and negatively correlate with patient survival [149] . Animal modeling has demonstrated that inflammatory responses in intestinal cancers start in aberrant crypts and early adenomatous polyps [150] [151] [152] . Inflammation correlated with focal accumulation of microbes [47 && ] and with the breakdown of epithelial barrier functions [153,154 & ]. Much of this inflammation was driven by TH17 cytokines [113, 155] whose genetic ablation (of IL-6, IL-23, and TNFa) in bone marrow-derived cells hindered polyp growth with varying efficacies [148 && ]. Interestingly, control of inflammation in mice with polyposis also enhanced polyp-specific TH1 response, increased intrapolyp cytolytic activity, and provided long-term protection [148 && ]. TH17 inflammation in polyposis is microbial driven, and we recently showed that colonization of the mouse colon with beneficial microbiota can increase Treg expression of IL-10, protect against inflammation, and hinder polyposis [156 && ]. TH17 responses are suppressed by IL-10-producing Tregs [140, [157] [158] [159] . The adoptive transfer of IL-10 proficient Tregs from healthy donor mice to recipient mice that have polyposis or are otherwise prone to intestinal carcinogenesis suppressed inflammation and protected mice from intestinal carcinogenesis [155, 160] . Only IL-10 competent Tregs were effective, and IL-10-deficient Tregs failed to prevent colitis [161] and carcinogenesis [155, 162] . T-cell-specific ablation of IL-10 in mice exacerbated microbe-driven inflammation and polyposis in the colon [47 && ]. Treg-specific ablation of IL-10 and germ-line deletion of IL-10 produced similar colonic inflammations emphasizing the role of Tregs as a major source of IL-10 in the control of microbial inflammation [159] . These observations define a central role for IL-10-expressing Tregs in control of pathogenic inflammation at environmental interfaces. In line with these findings, in a range of inflammation-driven cancers including colon [163,164 & , [165] [166] [167] , gastric [168] , and head and neck [169, 170] as well as HER2 þ breast cancer [171] , infiltration of tumors with Tregs is associated with less aggressive tumors and can be an independent predictor of longer patient survival. Altogether, these observations indicate that Treg expression of IL-10 is protective against colon cancer by suppresing cancer-associated inflammation and improving antitumor immune surveillance.
TH17 cells are responsible for orchestrating microbial-induced inflammation [172, 173] and are intimately linked with the control of microbiota [174 && ]. Expression of IL-17 is contingent upon activity of nuclear retinoic acid-related orphan receptor-gt (ROR-gt) [175] , RORa [176] , and Kruppel-like factor 4 (KLF4) [177] . Expression of IL-10 by Tregs is elevated in the intestines to control TH17 inflammation [19, 45, 178] . However, during polyposis in mice expression of IL-10 is down-regulated and Tregs acquire TH17-like characteristics including expression of the signature TH17 transcription factor RORgt as well as IL-17 [155] . Similarly, both circulating and tumor infiltrating Tregs in human colon cancer have compromised expression of IL-10, even though these remain potently T-cell suppressive and are unable to control inflammation [113,148 && ]. These characteristics are shared by Tregs derived from lung cancer and pancreatic cancer patients (our unpublished observations). Mouse modeling has demonstrated that the IL-10-deficient Treg subset significantly contributes to disease outcome [113,148 && ,155], as ablation of RORgt in the bone marrow-derived cells or even just in Tregs was sufficient to recover expression of IL-10 and protect mice against polyposis [148 && ]. These findings provide evidence for a central role of IL-10 in control of inflammation and immune surveillance (Fig. 1) , and open new possibilities for improving protective immunity at environmental surfaces through manipulation of this cross-talk.
Protective anti-inflammatory roles of IL-10 in cancer are gleaned from studies with preclinical models of cancer immune therapy. Therapies aimed at blocking the cytotoxic T-lymphocyte antigen-4 (CTLA4) inhibitory checkpoints have promoted antitumor immunity in mouse models of cancer and objective clinical benefits in cancer patients [179] . In mouse models, CTLA4 blockade expanded IL-10-producing CD4 þ FoxP3 þ Tregs in a dosedependent fashion [180] . In a mouse model of colitis, anti-CTLA-4 treatment induced IL-10 þ Tregs that expressed the cell surface receptor ICOS-ligand (ICOS-L) and had potent indoleamine 2,3-dioxygenase-dependent anti-inflammatory properties [181] . These observations are particularly interesting as expression of ICOS is an immunologic marker that correlates with clinical responses in prostate cancer patients who receive anti-CTLA-4 therapy [182] . Mouse modeling has revealed that expression of ICOS is intimately related to the production of IL-10 by Tregs [96, 183] and Tr1 cells [184] . Expression of ICOS and IL-10 were in turn related to protective antitumor immunity. Furthermore, Foxp3 þ precursors isolated from the human thymus that coexpressed ICOS preferentially upregulated IL-10 expression in response to stimulation with dendritic cells that express ICOS-L [185] . Together, these observations suggest that protective mechanisms of CTLA4 blockade involve induction of IL-10 and suppression of inflammation by Tregs.
CONCLUSION
Until recently, IL-10 was regarded as an immune suppressive cytokine that hindered antitumor immunity. It is becoming evident that IL-10 is essential for TH1 cell function and antitumor cytolytic activity. The potent anti-inflammatory functions of IL-10, which are mainly indirect and cellmediated, synergize with its immune stimulatory functions to improve tumor-specific immune surveillance. Knowledge gained thus far implicates IL-10 in the protective arm of the immune response Overarching hypothesis. Colon cancer is driven by microbial-associated inflammation. Typically this is a TH17 inflammation that is controlled by IL-10-expressing T-cells and Tregs. There is also a general consensus that cancer is controlled by immune surveillance and TH1 response. Ultimately, disease outcome is the product of both control of inflammation and effective immune surveillance. IL-10 is essential for both processes. IL-10, interleukin-10; TH17, T-helper-17; Tregs, regulatory T-cells.
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to at least those cancers that appear at environmental interfaces and are driven by microbial-instigated inflammation (Fig. 1) . This knowledge provides new opportunities of immune intervention in cancer.
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